Research Article

Multicomponent Therapeutics of Berberine Alkaloids

Figure 8

In vivo anti-MRSA effects of BAs combinations. (a) Body weight of ICR mice from day −3 to 16; (b) percent survival of ICR mice during the therapeutic process. (a: cefoxitin group; b: combination in Rhizoma Coptidis group; c: combination in Phellodendri Chinensis Cortex group; d: combination in Berberidis Radix group; e: optimal combination in this study group; f: geometric proportion of alkaloids group; g: negative group (noninfection mice without being given drugs); h: placebo control).
545898.fig.008a
(a)
545898.fig.008b
(b)